NO327806B1 - Anvendelse av promoterforbundet nukleinsyre ved fremstilling av et medikament egnet til avlevering til elektrisk stimulert muskel hos et pattedyr - Google Patents
Anvendelse av promoterforbundet nukleinsyre ved fremstilling av et medikament egnet til avlevering til elektrisk stimulert muskel hos et pattedyr Download PDFInfo
- Publication number
- NO327806B1 NO327806B1 NO19994820A NO994820A NO327806B1 NO 327806 B1 NO327806 B1 NO 327806B1 NO 19994820 A NO19994820 A NO 19994820A NO 994820 A NO994820 A NO 994820A NO 327806 B1 NO327806 B1 NO 327806B1
- Authority
- NO
- Norway
- Prior art keywords
- muscle
- muscles
- dna
- nucleic acid
- stimulated
- Prior art date
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 147
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 30
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 30
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims description 13
- 241000124008 Mammalia Species 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 229940079593 drug Drugs 0.000 title abstract description 27
- 239000007924 injection Substances 0.000 claims abstract description 55
- 238000002347 injection Methods 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 43
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 238000002649 immunization Methods 0.000 claims description 10
- 230000003053 immunization Effects 0.000 claims description 10
- 230000002068 genetic effect Effects 0.000 claims description 9
- 238000012385 systemic delivery Methods 0.000 claims 1
- 108010041986 DNA Vaccines Proteins 0.000 abstract description 3
- 229940021995 DNA vaccine Drugs 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000012546 transfer Methods 0.000 abstract description 3
- 230000028993 immune response Effects 0.000 abstract description 2
- 230000009885 systemic effect Effects 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 76
- 238000001890 transfection Methods 0.000 description 45
- 230000000638 stimulation Effects 0.000 description 39
- 239000000835 fiber Substances 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 26
- 239000013612 plasmid Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 210000001087 myotubule Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 102000003951 Erythropoietin Human genes 0.000 description 12
- 108090000394 Erythropoietin Proteins 0.000 description 12
- 229940105423 erythropoietin Drugs 0.000 description 12
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 108010005774 beta-Galactosidase Proteins 0.000 description 11
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 11
- 238000004520 electroporation Methods 0.000 description 10
- 239000005090 green fluorescent protein Substances 0.000 description 10
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 9
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229920002307 Dextran Polymers 0.000 description 8
- 101710128836 Large T antigen Proteins 0.000 description 8
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 210000000663 muscle cell Anatomy 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 101000993364 Homo sapiens Ciliary neurotrophic factor Proteins 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 101150079978 AGRN gene Proteins 0.000 description 4
- 108700019743 Agrin Proteins 0.000 description 4
- 102100040026 Agrin Human genes 0.000 description 4
- 208000029549 Muscle injury Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000003497 sciatic nerve Anatomy 0.000 description 4
- 239000008279 sol Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 101000959590 Rattus norvegicus Agrin Proteins 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 108700028044 Ala(152)-Ala(155)-Asp(166)-His(167)- ciliary neurotrophic factor Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 101000987583 Mus musculus Eosinophil peroxidase Proteins 0.000 description 1
- 101000920670 Mus musculus Erythropoietin Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/205—Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Electrotherapy Devices (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4259497P | 1997-04-03 | 1997-04-03 | |
| PCT/IB1998/000487 WO1998043702A2 (fr) | 1997-04-03 | 1998-04-03 | Methode pour introduire des medicaments et des acides nucleiques dans le muscle squelettique |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO994820D0 NO994820D0 (no) | 1999-10-04 |
| NO994820L NO994820L (no) | 1999-12-03 |
| NO327806B1 true NO327806B1 (no) | 2009-09-28 |
Family
ID=21922760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19994820A NO327806B1 (no) | 1997-04-03 | 1999-10-04 | Anvendelse av promoterforbundet nukleinsyre ved fremstilling av et medikament egnet til avlevering til elektrisk stimulert muskel hos et pattedyr |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6110161A (fr) |
| EP (1) | EP1023107B1 (fr) |
| JP (2) | JP2001520537A (fr) |
| KR (1) | KR100427786B1 (fr) |
| CN (1) | CN1198665C (fr) |
| AT (1) | ATE337794T1 (fr) |
| AU (1) | AU733628B2 (fr) |
| CA (1) | CA2285056C (fr) |
| DE (1) | DE69835761T2 (fr) |
| DK (1) | DK1023107T3 (fr) |
| EA (1) | EA002087B1 (fr) |
| ES (1) | ES2273408T3 (fr) |
| IL (1) | IL132103A0 (fr) |
| NO (1) | NO327806B1 (fr) |
| NZ (1) | NZ337853A (fr) |
| WO (1) | WO1998043702A2 (fr) |
Families Citing this family (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
| US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| US6261281B1 (en) * | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| EP0991426B2 (fr) | 1997-06-30 | 2007-03-28 | Institut Gustave Roussy | Procede de transfert d'acide nucleique dans le muscle strie |
| DE69829287T2 (de) * | 1997-06-30 | 2006-04-13 | Centre National De La Recherche Scientifique (Cnrs) | Verbesserung der verabreichung der nukleinsäure in zellen der plurizellulären eukaryotischen organismen und kombination zur durchführung des verfahrens |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US20040229363A1 (en) * | 1998-06-24 | 2004-11-18 | Ed Nolan | High efficiency transfection based on low electric field strength, long pulse length |
| JP2003505114A (ja) | 1998-07-13 | 2003-02-12 | ジェネトロニクス、インコーポレーテッド | パルス電場による皮膚および筋肉を標的とした遺伝子治療 |
| US7922709B2 (en) | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
| US6678556B1 (en) * | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
| EP1148885A4 (fr) * | 1999-02-08 | 2002-05-08 | Chiron Corp | Augmentation electriquement induite de l'immunite et de l'efficacite de vaccins d'adn in vivo |
| US6593130B1 (en) | 1999-04-16 | 2003-07-15 | The Regents Of The University Of California | Method and apparatus for ex vivo and in vivo cellular electroporation of gene protein or drug therapy |
| CA2401239A1 (fr) * | 2000-03-03 | 2001-09-13 | Valentis, Inc. | Compositions ameliorees de poloxamere et de poloxamine generatrices d'acide nucleique |
| JP2004532654A (ja) | 2000-05-22 | 2004-10-28 | マーク・アンド・カンパニー・インコーポレイテッド | 薬剤投与システム性能評価システム及び方法 |
| US6733485B1 (en) | 2001-05-25 | 2004-05-11 | Advanced Bionics Corporation | Microstimulator-based electrochemotherapy methods and systems |
| US20040204669A1 (en) * | 2001-07-05 | 2004-10-14 | Hofmann Gunter A. | Apparatus for electroporation mediated delivery for drugs and genes |
| US7713740B2 (en) * | 2001-08-24 | 2010-05-11 | University Of South Florida | Method of using electric fields to facilitate the entry of molecules into cells in vivo |
| ATE467680T1 (de) | 2001-10-11 | 2010-05-15 | Merck Sharp & Dohme | Hepatitis-c-virus-impfstoff |
| CN1880457B (zh) | 2001-10-11 | 2010-05-26 | 麦克公司 | Ad6重组核酸 |
| CN1612691A (zh) * | 2001-11-08 | 2005-05-04 | 加利福尼亚大学董事会 | 纠正心脏传导障碍的方法和组合物 |
| AU2002360648B2 (en) * | 2001-12-14 | 2009-01-08 | Genetronics, Inc. | Methods for particle-assisted polynucleotide immunization using a pulsed electric field |
| JP2005527490A (ja) * | 2002-01-18 | 2005-09-15 | イノヴィオ アーエス | 筋肉内投与のための二重特異性抗体ｄｎａ構築物 |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7245963B2 (en) * | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| EP1480692A2 (fr) | 2002-03-07 | 2004-12-01 | Merck & Co., Inc. | Seringue clinique avec des aspects de stimulation electrique |
| US6912417B1 (en) * | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
| AU2003223351A1 (en) | 2002-04-16 | 2003-11-03 | Cyto Pulse Sciences, Inc. | Method of treating biological materials with translating electrical fields and electrode polarity reversal |
| US20040106896A1 (en) * | 2002-11-29 | 2004-06-03 | The Regents Of The University Of California | System and method for forming a non-ablative cardiac conduction block |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| SG136133A1 (en) | 2004-03-08 | 2007-10-29 | Ichor Medical Systems Inc Ca U | Improved apparatus for electrically mediated delivery of therapeutic agents |
| TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
| JP2008532560A (ja) | 2005-03-19 | 2008-08-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 微弱電界ネットワークを仲介して行う、生体外で細胞内に遺伝子、タンパク質および薬剤を送達する方法および装置 |
| JP5475279B2 (ja) | 2005-06-17 | 2014-04-16 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | Ｃ型肝炎ウイルス核酸ワクチン |
| US20070190032A1 (en) * | 2006-02-13 | 2007-08-16 | Oncolytics Biotech Inc. | Use of Local Immune Suppression to Enhance Oncolytic Viral Therapy |
| CA2668649A1 (fr) | 2006-11-17 | 2008-05-29 | Genetronics, Inc. | Methodes accroissant la reponse immunitaire par vaccination assistee par electroporation, et renfort |
| CN101998965B (zh) | 2007-11-01 | 2014-03-12 | 安斯泰来制药有限公司 | 免疫抑制性多肽与核酸 |
| JP5744719B2 (ja) * | 2008-04-04 | 2015-07-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法 |
| JP5873717B2 (ja) * | 2008-04-04 | 2016-03-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｉｌ−２８及び組成物を用いたワクチン及び免疫治療薬並びにその使用方法 |
| EP2147697A1 (fr) | 2008-07-21 | 2010-01-27 | Centre National De La Recherche Scientifique-CNRS | Procédé et dispositif pour appliquer des champs électriques dans un matériau conducteur |
| EP2156860A1 (fr) | 2008-08-20 | 2010-02-24 | Centre National De La Recherche Scientifique-CNRS | Procédé de fabrication d'électrodes isolées pour l'application de champs électriques dans un matériau conducteur |
| US8207138B2 (en) | 2009-05-19 | 2012-06-26 | Medtronic, Inc. | Methods and devices for improved efficiency of RNA delivery to cells |
| US20100298697A1 (en) * | 2009-05-19 | 2010-11-25 | Medtronic, Inc. | Method and devices for improved efficiency of rna delivery to cells |
| CN102821790A (zh) | 2009-09-14 | 2012-12-12 | 宾夕法尼亚大学托管会 | 包含IL-15受体α和/或编码IL-15受体α的核酸分子的疫苗和免疫治疗剂,以及其使用方法 |
| KR20210149203A (ko) | 2009-11-02 | 2021-12-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 구제역 바이러스(ｆｍｄｖ) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신 |
| US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| CN102781952B (zh) | 2010-02-08 | 2015-09-02 | 宾夕法尼亚大学托管会 | 编码rantes的核酸分子、包含其的组合物以及其使用方法 |
| AU2011312465B2 (en) | 2010-09-27 | 2015-07-23 | Inovio Pharmaceuticals, Inc | Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria |
| MX346784B (es) | 2010-11-12 | 2017-03-31 | Inovio Pharmaceuticals Inc | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. |
| EP2670443A4 (fr) | 2011-01-31 | 2015-10-14 | Univ Pennsylvania | Molécules d'acide nucléique codant de nouveaux antigènes d'herpès, vaccin les comprenant et procédés pour les utiliser |
| PT2672992T (pt) | 2011-02-11 | 2020-07-27 | Univ Pennsylvania | Molécula de ácidos nucleicos codificando proteína nuclear do vírus da hepatite b e vacina compreendendo a mesma |
| US9238679B2 (en) | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
| US9457183B2 (en) | 2011-06-15 | 2016-10-04 | Tripep Ab | Injection needle and device |
| CA2841852C (fr) | 2011-07-11 | 2020-06-30 | Inovio Pharmaceuticals, Inc. | Vaccins fournissant une protection croisee contre les arenavirus et leur procede d'utilisation |
| JP6407028B2 (ja) | 2011-12-12 | 2018-10-17 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 |
| US9272024B2 (en) | 2011-12-12 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same |
| EP2836505B1 (fr) | 2012-04-10 | 2019-01-23 | The Trustees Of The University Of Pennsylvania | Antigènes consensus du virus syncytial respiratoire humain, constructions d'acide nucléique et vaccins préparés à partir de celles-ci, et leurs procédés d'utilisation |
| KR20240010758A (ko) | 2012-04-12 | 2024-01-24 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법 |
| DE102012013534B3 (de) | 2012-07-05 | 2013-09-19 | Tobias Sokolowski | Vorrichtung für repetitive Nervenstimulation zum Abbau von Fettgewebe mittels induktiver Magnetfelder |
| WO2014064534A2 (fr) | 2012-10-05 | 2014-05-01 | Chrontech Pharma Ab | Aiguille d'injection, dispositif, compositions immunogènes et procédé d'utilisation |
| SI2931304T1 (sl) | 2012-12-13 | 2021-11-30 | The Trustees Of The University Of Pennsylvania | Cepivo proti WT1 |
| KR20230062674A (ko) | 2013-03-15 | 2023-05-09 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 암 백신 및 이를 이용한 치료 방법 |
| BR112015022582B1 (pt) | 2013-03-15 | 2024-01-09 | The Trustees Of The University Of Pennsylvania | Molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo |
| WO2015017734A1 (fr) | 2013-07-31 | 2015-02-05 | Board Of Trustees Of The University Of Arkansas | Compositions et méthodes permettant de traiter et de prévenir le cancer par ciblage des antigènes glucidiques associés à la tumeur |
| CN105829341A (zh) | 2013-12-13 | 2016-08-03 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
| CA2969214A1 (fr) | 2014-12-01 | 2016-06-09 | The Trustees Of The University Of Pennsylvania | Constructions d'anticorps d'adn et leur procede d'utilisation |
| US11491342B2 (en) | 2015-07-01 | 2022-11-08 | Btl Medical Solutions A.S. | Magnetic stimulation methods and devices for therapeutic treatments |
| US10695575B1 (en) | 2016-05-10 | 2020-06-30 | Btl Medical Technologies S.R.O. | Aesthetic method of biological structure treatment by magnetic field |
| US20180001107A1 (en) | 2016-07-01 | 2018-01-04 | Btl Holdings Limited | Aesthetic method of biological structure treatment by magnetic field |
| US11266850B2 (en) | 2015-07-01 | 2022-03-08 | Btl Healthcare Technologies A.S. | High power time varying magnetic field therapy |
| WO2017055522A1 (fr) | 2015-09-29 | 2017-04-06 | Academisch Medisch Centrum | Protéines env stabilisées du vih |
| US11253717B2 (en) | 2015-10-29 | 2022-02-22 | Btl Healthcare Technologies A.S. | Aesthetic method of biological structure treatment by magnetic field |
| JP7123800B2 (ja) | 2016-02-05 | 2022-08-23 | イノビオ ファーマシューティカルズ，インコーポレイティド | がんのワクチン及びそれを用いた処置の方法 |
| IL296595A (en) | 2016-03-28 | 2022-11-01 | Ichor Medical Systems Inc | Method and device for administering medical substances |
| US10538786B2 (en) | 2016-04-13 | 2020-01-21 | Janssen Pharmaceuticals, Inc. | Recombinant arterivirus replicon systems and uses thereof |
| US11247039B2 (en) | 2016-05-03 | 2022-02-15 | Btl Healthcare Technologies A.S. | Device including RF source of energy and vacuum system |
| US11464993B2 (en) | 2016-05-03 | 2022-10-11 | Btl Healthcare Technologies A.S. | Device including RF source of energy and vacuum system |
| US11534619B2 (en) | 2016-05-10 | 2022-12-27 | Btl Medical Solutions A.S. | Aesthetic method of biological structure treatment by magnetic field |
| US10583287B2 (en) | 2016-05-23 | 2020-03-10 | Btl Medical Technologies S.R.O. | Systems and methods for tissue treatment |
| US10556122B1 (en) | 2016-07-01 | 2020-02-11 | Btl Medical Technologies S.R.O. | Aesthetic method of biological structure treatment by magnetic field |
| KR20190082226A (ko) | 2016-10-17 | 2019-07-09 | 신테틱 제노믹스, 인코포레이티드. | 재조합 바이러스 레플리콘 시스템 및 그의 용도 |
| BR112019011661A2 (pt) | 2016-12-05 | 2020-01-07 | Synthetic Genomics, Inc. | Composições e métodos para aumentar expressão de gene |
| US11344618B2 (en) | 2017-08-26 | 2022-05-31 | Academisch Medisch Centrum | HIV envelope glycoprotein immunogens |
| EP3723812A4 (fr) | 2017-12-13 | 2022-02-16 | Inovio Pharmaceuticals, Inc. | Vaccins anticancer ciblant muc16 et leurs utilisations |
| EP3737397B1 (fr) | 2017-12-13 | 2022-11-30 | Inovio Pharmaceuticals, Inc. | Vaccins anticancéreux ciblant l'antigène exprimé de façon préférentielle dans le mélanome (prame) et ses utilisations |
| KR102637862B1 (ko) | 2017-12-13 | 2024-02-19 | 이노비오 파마수티컬즈, 인크. | 메소텔린을 표적으로 하는 암 백신 및 이의 용도 |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| CA3086327A1 (fr) | 2017-12-19 | 2019-06-27 | Janssen Sciences Ireland Unlimited Company | Vaccins contre le virus de l'hepatite b (vhb) et utilisations associees |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| KR20200100745A (ko) | 2017-12-19 | 2020-08-26 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물 |
| WO2019143949A2 (fr) | 2018-01-19 | 2019-07-25 | Synthetic Genomics, Inc. | Induction et amélioration des réponses immunitaires à l'aide de systèmes de réplicon de recombinaison |
| CA3116569C (fr) | 2019-04-11 | 2023-08-15 | Btl Medical Technologies S.R.O. | Procedes et dispositifs de traitement esthetique de structures biologiques par radiofrequence et energie magnetique |
| WO2020255035A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de pyrimidine |
| TWI772823B (zh) | 2019-06-18 | 2022-08-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | B型肝炎病毒(hbv)疫苗與蛋白殼組裝調節劑之組合 |
| EP3986915A1 (fr) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Construction de l'interleukine 12 recombinante et ses utilisations |
| WO2020254876A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Administration de particules de type viral de vaccins contre le virus de l'hépatite b (vhb) |
| JP2022536945A (ja) | 2019-06-18 | 2022-08-22 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ |
| WO2020255038A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Association de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de pyridopyrimidine |
| WO2020255022A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de dérivés d'aminopyridine en tant qu'inhibiteurs de hpk1 |
| CA3140702A1 (fr) | 2019-06-18 | 2020-12-24 | Helen Horton | Combinaison de vaccins contre le virus de l'hepatite b (vhb) et de derives de dihydropyrimidine en tant que modulateurs d'assemblage de capside |
| AU2020296372A1 (en) | 2019-06-18 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis B virus (HBV) vaccines and anti-PD-1 antibody |
| WO2020255016A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de dihydropyrimidine en tant que modulateurs de l'assemblage des capsides |
| WO2020255042A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'un dérivé de pyrimidine |
| WO2020255011A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1 ou anti-pd-l1 |
| CA3140588A1 (fr) | 2019-06-18 | 2020-12-24 | Helen Horton | Combinaison de vaccins contre le virus de l'hepatite b (vhb) et d'inhibiteur de pdl1 ou pd1 a petite molecule |
| WO2020255010A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combinaison d'une construction d'interleukine 12 recombinante et de vaccins contre le virus de l'hépatite b (vhb) |
| CA3140707A1 (fr) | 2019-06-18 | 2020-12-24 | Helen Horton | Association de vaccins contre le virus de l'hepatite b (vhb) et de derives de quinazoline |
| WO2020255020A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Association de vaccins contre le virus de l'hépatite b (vhb) et d'inhibiteurs de pd-l1 |
| CA3141238A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Vaccins contre le virus de l'hepatite b (vhb) et utilisations associees |
| AU2020297008A1 (en) | 2019-06-18 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis B virus (HBV) vaccines and HBV-targeting RNAi |
| WO2020255013A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de modulateurs d'assemblage de capside qui sont des dérivés d'amide |
| CA3140690A1 (fr) | 2019-06-18 | 2020-12-24 | Helen Horton | Combinaison de vaccins contre le virus de l'hepatite b (vhb) et de derives de dihydropyrimidine en tant que modulateurs d'assemblage de capside |
| WO2020255019A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'un dérivé de la quinazoline |
| US20220305118A1 (en) | 2019-06-20 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines |
| AU2020295807A1 (en) | 2019-06-20 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis B virus (HBV) vaccines |
| CA3173876A1 (fr) | 2020-05-04 | 2021-11-11 | Tomas SCHWARZ | Dispositif et methode pour traitement automatise d'un patient |
| US11878167B2 (en) | 2020-05-04 | 2024-01-23 | Btl Healthcare Technologies A.S. | Device and method for unattended treatment of a patient |
| CA3181680A1 (fr) | 2020-06-12 | 2021-12-16 | University Of Rochester | Codage et expression d'arnt ace |
| CA3188801A1 (fr) | 2020-07-08 | 2022-01-13 | Janssen Sciences Ireland Unlimited Company | Vaccins a base de replicon d'arn contre le vhb |
| TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| EP4267740A1 (fr) | 2020-12-28 | 2023-11-01 | Arcturus Therapeutics, Inc. | Nucléases effectrices de type activateur de transcription (talens) ciblant le vhb |
| US11896816B2 (en) | 2021-11-03 | 2024-02-13 | Btl Healthcare Technologies A.S. | Device and method for unattended treatment of a patient |
| WO2023150753A1 (fr) | 2022-02-07 | 2023-08-10 | University Of Rochester | Séquences optimisées pour une expression d'adn améliorée et/ou une suppression de mutation non sens |
| WO2023233290A1 (fr) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Agents d'arni ciblant pd-l1 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5389069A (en) * | 1988-01-21 | 1995-02-14 | Massachusetts Institute Of Technology | Method and apparatus for in vivo electroporation of remote cells and tissue |
| US5501662A (en) * | 1992-05-22 | 1996-03-26 | Genetronics, Inc. | Implantable electroporation method and apparatus for drug and gene delivery |
| US5304120A (en) * | 1992-07-01 | 1994-04-19 | Btx Inc. | Electroporation method and apparatus for insertion of drugs and genes into endothelial cells |
| US5273525A (en) * | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| US5318514A (en) * | 1992-08-17 | 1994-06-07 | Btx, Inc. | Applicator for the electroporation of drugs and genes into surface cells |
| US5468223A (en) * | 1992-11-30 | 1995-11-21 | C.N.R.S. Paris | Electrochemotherapy |
| FR2703253B1 (fr) * | 1993-03-30 | 1995-06-23 | Centre Nat Rech Scient | Applicateur d'impulsions electriques pour traitement de tissus biologiques. |
| US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
| IL108775A (en) * | 1994-02-25 | 2003-09-17 | Univ Ramot | Method for efficient incorporation of molecules into cells |
| JPH10502858A (ja) * | 1995-05-02 | 1998-03-17 | フィリップス エレクトロニクス エヌ ベー | 対象の磁気共鳴画像化方法及び装置 |
| US5944710A (en) * | 1996-06-24 | 1999-08-31 | Genetronics, Inc. | Electroporation-mediated intravascular delivery |
| DE69829287T2 (de) * | 1997-06-30 | 2006-04-13 | Centre National De La Recherche Scientifique (Cnrs) | Verbesserung der verabreichung der nukleinsäure in zellen der plurizellulären eukaryotischen organismen und kombination zur durchführung des verfahrens |
-
1998
- 1998-04-03 IL IL13210398A patent/IL132103A0/xx unknown
- 1998-04-03 DK DK98909691T patent/DK1023107T3/da active
- 1998-04-03 CA CA002285056A patent/CA2285056C/fr not_active Expired - Lifetime
- 1998-04-03 CN CNB98803980XA patent/CN1198665C/zh not_active Expired - Lifetime
- 1998-04-03 DE DE69835761T patent/DE69835761T2/de not_active Expired - Lifetime
- 1998-04-03 AU AU69906/98A patent/AU733628B2/en not_active Expired
- 1998-04-03 ES ES98909691T patent/ES2273408T3/es not_active Expired - Lifetime
- 1998-04-03 WO PCT/IB1998/000487 patent/WO1998043702A2/fr active IP Right Grant
- 1998-04-03 NZ NZ337853A patent/NZ337853A/en not_active IP Right Cessation
- 1998-04-03 US US09/055,084 patent/US6110161A/en not_active Expired - Lifetime
- 1998-04-03 AT AT98909691T patent/ATE337794T1/de active
- 1998-04-03 EA EA199900882A patent/EA002087B1/ru not_active IP Right Cessation
- 1998-04-03 JP JP54134898A patent/JP2001520537A/ja active Pending
- 1998-04-03 EP EP98909691A patent/EP1023107B1/fr not_active Expired - Lifetime
- 1998-04-03 KR KR10-1999-7009009A patent/KR100427786B1/ko not_active IP Right Cessation
-
1999
- 1999-10-04 NO NO19994820A patent/NO327806B1/no not_active IP Right Cessation
-
2005
- 2005-09-01 JP JP2005253462A patent/JP2006061701A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US6110161A (en) | 2000-08-29 |
| JP2006061701A (ja) | 2006-03-09 |
| EA002087B1 (ru) | 2001-12-24 |
| IL132103A0 (en) | 2001-03-19 |
| NO994820L (no) | 1999-12-03 |
| CN1276740A (zh) | 2000-12-13 |
| KR100427786B1 (ko) | 2004-04-30 |
| AU6990698A (en) | 1998-10-22 |
| EP1023107B1 (fr) | 2006-08-30 |
| ATE337794T1 (de) | 2006-09-15 |
| CA2285056C (fr) | 2004-12-14 |
| KR20010005932A (ko) | 2001-01-15 |
| DK1023107T3 (da) | 2006-12-27 |
| CN1198665C (zh) | 2005-04-27 |
| EA199900882A1 (ru) | 2001-02-26 |
| CA2285056A1 (fr) | 1998-10-08 |
| EP1023107A1 (fr) | 2000-08-02 |
| AU733628B2 (en) | 2001-05-17 |
| DE69835761T2 (de) | 2007-09-13 |
| WO1998043702A2 (fr) | 1998-10-08 |
| NO994820D0 (no) | 1999-10-04 |
| JP2001520537A (ja) | 2001-10-30 |
| DE69835761D1 (de) | 2006-10-12 |
| NZ337853A (en) | 2002-03-28 |
| ES2273408T3 (es) | 2007-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO327806B1 (no) | Anvendelse av promoterforbundet nukleinsyre ved fremstilling av et medikament egnet til avlevering til elektrisk stimulert muskel hos et pattedyr | |
| US6261281B1 (en) | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells | |
| Sokołowska et al. | A critical review of electroporation as a plasmid delivery system in mouse skeletal muscle | |
| US7171264B1 (en) | Intradermal delivery of active agents by needle-free injection and electroporation | |
| McMahon et al. | Electroporation for gene transfer to skeletal muscles: current status | |
| EP1648555B1 (fr) | Méthode pour introduire un agent dans une cellule | |
| US20080045880A1 (en) | Device and method for single-needle in vivo electroporation | |
| CN101085363A (zh) | 肝细胞生长因子基因的应用 | |
| JP7448603B2 (ja) | 電気穿孔を使用した、脂肪組織の低侵襲のｉｎ ｖｉｖｏトランスフェクションのための方法及び装置 | |
| Richard et al. | Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles | |
| Nosaka | Electrophysiologic identification of preganglionic neurons in rat dorsal motor nucleus and analysis of vagus afferent projections | |
| US20080287857A1 (en) | Device and method for single-needle in vivo electroporation | |
| CA2395492A1 (fr) | Procede et appareil permettant de cibler une electroporation localisee | |
| Boye et al. | Reduction of plasmid vector backbone length enhances reporter gene expression | |
| MXPA99009026A (en) | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle | |
| Kos et al. | Utilization of multi-array electrodes for delivery of drugs and genes in the mouse skin | |
| Bigeya et al. | ELECTROTRANSFER/ELECTROPORATION FOR NON-VIRAL NUCLEIC ACID DELIVERY | |
| US20220162275A1 (en) | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof | |
| Bui | Biphasic Gene Electrotransfer Enhances Gene Delivery in Vitro | |
| Rosen et al. | Regenerative therapies in electrophysiology and pacing | |
| Draghia-Akli et al. | Innovative electroporation for therapeutic and vaccination applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |